A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight used it ...

Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like ...

Tirzepatide and semaglutide are type 2 diabetes drugs often used for weight loss. Tirzepatide is less expensive and may be more effective. However, the drug is still new, and more research is needed.

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant weight loss in obese mice but also slashed breast cancer tumor growth. The ...

A clinical trial found that a high dose of tirzepatide — which was previously approved for diabetes treatment — helped patients lose an average of 22.5% of their body weight Tirzepatide, a new drug ...

The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA announced Thursday. As a result, compounders will have a grace period of 60 to 90 days ...

The latest buzzy diabetes drug semaglutide—better known by brand names Ozempic, Wegovy, and Rybelsus—is drawing attention for its ability to both control blood sugar and cause weight loss. But doctors ...

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, ...

Please provide your email address to receive an email when new articles are posted on . The FDA sent warning letters to US Chem Labs and Synthetic Inc. for offering unapproved semaglutide and ...

Eli Lilly’s weight loss injection tirzepatide — the ingredient inside its wildly popular drugs Mounjaro and Zepbound — could also help treat sleep apnea, according to research published Friday, a ...